Literature DB >> 25079909

A mutation in X-linked inhibitor of apoptosis (G466X) leads to memory inflation of Epstein-Barr virus-specific T cells.

E Lopez-Granados1, M Stacey, A-K Kienzler, S Sierro, C B Willberg, C P Fox, S Rigaud, H M Long, A D Hislop, A B Rickinson, S Patel, S Latour, P Klenerman, H Chapel.   

Abstract

Mutations in the X-linked inhibitor of apoptosis (XIAP) gene have been associated with XLP-like disease, including recurrent Epstein-Barr virus (EBV)-related haemophagocytic lymphohystiocytosis (HLH), but the immunopathogenic bases of EBV-related disease in XIAP deficiency is unknown. We present the first analysis of EBV-specific T cell responses in functional XIAP deficiency. In a family of patients with a novel mutation in XIAP (G466X) leading to a late-truncated protein and varying clinical features, we identified gradual hypogammaglobulinaemia and large expansions of T cell subsets, including a prominent CD4(+) CD8(+) population. Extensive ex-vivo analyses showed that the expanded T cell subsets were dominated by EBV-specific cells with conserved cytotoxic, proliferative and interferon (IFN)-γ secretion capacity. The EBV load in blood fluctuated and was occasionally very high, indicating that the XIAP(G466X) mutation could impact upon EBV latency. XIAP deficiency may unravel a new immunopathogenic mechanism in EBV-associated disease.
© 2014 British Society for Immunology.

Entities:  

Keywords:  T cells; cytotoxic T cells; immunodeficiency diseases; viral

Mesh:

Substances:

Year:  2014        PMID: 25079909      PMCID: PMC4238874          DOI: 10.1111/cei.12427

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  35 in total

1.  Impaired transporter associated with antigen processing-dependent peptide transport during productive EBV infection.

Authors:  Maaike E Ressing; Sinéad E Keating; Daphne van Leeuwen; Danijela Koppers-Lalic; Isabel Y Pappworth; Emmanuel J H J Wiertz; Martin Rowe
Journal:  J Immunol       Date:  2005-06-01       Impact factor: 5.422

2.  Expression of the Epstein Barr virus transforming protein LMP1 causes a rapid and transient stimulation of the Bcl-2 homologue Mcl-1 levels in B-cell lines.

Authors:  S Wang; M Rowe; E Lundgren
Journal:  Cancer Res       Date:  1996-10-15       Impact factor: 12.701

3.  Assessment of the effect of TLR7/8, TLR9 agonists and CD40 ligand on the transformation efficiency of Epstein-Barr virus in human B lymphocytes by limiting dilution assay.

Authors:  Vahid Younesi; Forough Golsaz Shirazi; Ali Memarian; Amir Amanzadeh; Mahmood Jeddi-Tehrani; Fazel Shokri
Journal:  Cytotechnology       Date:  2013-02-13       Impact factor: 2.058

4.  A single strand conformation polymorphism study of CD40 ligand. Efficient mutation analysis and carrier detection for X-linked hyper IgM syndrome.

Authors:  Q Lin; J Rohrer; R C Allen; M Larché; J M Greene; A O Shigeoka; R A Gatti; D C Derauf; J W Belmont; M E Conley
Journal:  J Clin Invest       Date:  1996-01-01       Impact factor: 14.808

Review 5.  B cells under influence: transformation of B cells by Epstein-Barr virus.

Authors:  Ralf Küppers
Journal:  Nat Rev Immunol       Date:  2003-10       Impact factor: 53.106

6.  X-linked inhibitor of apoptosis (XIAP) deficiency: the spectrum of presenting manifestations beyond hemophagocytic lymphohistiocytosis.

Authors:  C Speckmann; K Lehmberg; M H Albert; R B Damgaard; M Fritsch; M Gyrd-Hansen; A Rensing-Ehl; T Vraetz; B Grimbacher; U Salzer; I Fuchs; H Ufheil; B H Belohradsky; A Hassan; C M Cale; M Elawad; B Strahm; S Schibli; M Lauten; M Kohl; J J Meerpohl; B Rodeck; R Kolb; W Eberl; J Soerensen; H von Bernuth; M Lorenz; K Schwarz; U Zur Stadt; S Ehl
Journal:  Clin Immunol       Date:  2013-07-31       Impact factor: 3.969

7.  Human X-linked variable immunodeficiency caused by a hypomorphic mutation in XIAP in association with a rare polymorphism in CD40LG.

Authors:  Stéphanie Rigaud; Eduardo Lopez-Granados; Sophie Sibéril; Geoffrey Gloire; Nathalie Lambert; Christelle Lenoir; Cindy Synaeve; Maria Stacey; Lars Fugger; Jean-Louis Stephan; Alain Fischer; Capucine Picard; Anne Durandy; Helen Chapel; Sylvain Latour
Journal:  Blood       Date:  2011-05-04       Impact factor: 22.113

Review 8.  Virus-specific CD4+ T cells: ready for direct attack.

Authors:  Kevin N Heller; Cagan Gurer; Christian Münz
Journal:  J Exp Med       Date:  2006-03-20       Impact factor: 14.307

9.  SAP controls the cytolytic activity of CD8+ T cells against EBV-infected cells.

Authors:  Loïc Dupré; Grazia Andolfi; Stuart G Tangye; Rita Clementi; Franco Locatelli; Maurizio Aricò; Alessandro Aiuti; Maria-Grazia Roncarolo
Journal:  Blood       Date:  2005-01-27       Impact factor: 22.113

Review 10.  Cellular responses to viral infection in humans: lessons from Epstein-Barr virus.

Authors:  Andrew D Hislop; Graham S Taylor; Delphine Sauce; Alan B Rickinson
Journal:  Annu Rev Immunol       Date:  2007       Impact factor: 28.527

View more
  5 in total

1.  Interstitial lung disease in patients with common variable immunodeficiency disorders: several different pathologies?

Authors:  S Patel; C Anzilotti; M Lucas; N Moore; H Chapel
Journal:  Clin Exp Immunol       Date:  2019-07-10       Impact factor: 4.330

Review 2.  Infection-induced inflammation from specific inborn errors of immunity to COVID-19.

Authors:  Cheng-Lung Ku; I-Ting Chen; Ming-Zong Lai
Journal:  FEBS J       Date:  2021-05-20       Impact factor: 5.622

Review 3.  The (gradual) rise of memory inflation.

Authors:  Paul Klenerman
Journal:  Immunol Rev       Date:  2018-05       Impact factor: 12.988

Review 4.  Evolution of Our Understanding of XIAP Deficiency.

Authors:  Anne C A Mudde; Claire Booth; Rebecca A Marsh
Journal:  Front Pediatr       Date:  2021-06-17       Impact factor: 3.418

Review 5.  Epstein-Barr Virus (EBV)-Related Lymphoproliferative Disorders in Ataxia Telangiectasia: Does ATM Regulate EBV Life Cycle?

Authors:  Moussab Tatfi; Olivier Hermine; Felipe Suarez
Journal:  Front Immunol       Date:  2019-01-04       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.